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Abstract The polymorphic human cytochrome P450 2A6
(CYP2A6) metabolises a number of drugs, activates a variety
of precarcinogens and constitutes the major nicotine C-oxidase.
A relationship between CYP2A6 genotype and smoking habits,
as well as incidence of lung cancer, has been proposed. Two
defective alleles have hitherto been identified, one of which is very
common in Asian populations. Among Caucasians, an additional
defective and frequently distributed allele (CYP2A6*3) has been
suggested to play a protective role against nicotine addiction and
cigarette consumption. Here, we have re-evaluated the genotyp-
ing method used for the CYP2A6*3 allele and found that a gene
conversion in the 3P flanking region of 30^40% of CYP2A6*1
alleles results in genotype misclassification. In fact, no true
CYP2A6*3 alleles were found among 100 Spaniards and 96
Chinese subjects. In one Spanish poor metaboliser of the
CYP2A6 probe drug coumarin, we found two novel defective
alleles. One, CYP2A6*5, encoded an unstable enzyme having a
G479L substitution and the other was found to carry a novel type
of CYP2A6 gene deletion (CYP2A6*4D). The results imply the
presence of numerous defective as well as active CYP2A6 alleles
as a consequence of CYP2A6/CYP2A7 gene conversion events.
We conclude that molecular epidemiological studies concerning
CYP2A6 require validated genotyping methods for accurate
detection of all known defective CYP2A6 alleles.
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1. Introduction
The cytochromes P450 are a superfamily of enzymes in-
volved in the metabolism of numerous exogenous and endog-
enous substances including drugs, environmental chemicals,
steroid hormones and bile acids. Many of the genes that en-
code the drug metabolising P450s are to a high extent poly-
morphic, thereby causing pronounced interindividual variabil-
ity in the metabolism of many clinically used drugs [1].
Cytochrome P450 2A6 (CYP2A6) is a hepatic P450 which
metabolises certain pharmaceutical agents, e.g. coumarin, (+)-
cis-3,5-dimethyl-2-(3-pyridyl) thiozolidin-4-one hydrochloride
(SM-12502), methoxy£urane, halothane, losigamone, letro-
zole, valproic acid and disul¢ram. The enzyme can also
activate a number of precarcinogens, including 4-methylni-
trosamino-1-(3-pyridyl)-1-butanone (NNK), N-nitrosodiethyl-
amine, 1,3-butadiene and 2,6-dichlorobenzonitrile (see [2] for
references). In humans, the major pathway for nicotine me-
tabolism consists of its C-oxidation to cotinine followed by
cotinine 3P-hydroxylation [3], with CYP2A6 being the major
enzyme that catalyses both of these reactions [4^8].
Phenotyping studies done with the probe drug coumarin
have revealed pronounced interindividual variability in
CYP2A6 activity in vivo [9^12]. Similar results have been
obtained when CYP2A6 levels and activity were determined
in human liver microsomes [13^15]. Despite the great interin-
dividual variation observed, very few individuals lacking
CYP2A6 activity have been found in Caucasians [2,16]. The
frequency of poor metabolisers (PMs) in European and Mid-
dle East populations is 9 1%, whereas it is much higher in
Asian populations.
Genetic polymorphisms of the CYP2A6 gene can probably
explain this interindividual variability to a great extent. Two
types of defective alleles have been described thus far. The
CYP2A6*21 allele encodes an enzyme with a L160H substitu-
tion that does not incorporate haem and is therefore inactive
[17]. We and others [18,19] have also described some inactive
alleles common in Asian populations where parts of or the
whole CYP2A6 gene has been deleted (CYP2A6*4A, *4B and
*4C). In addition, CYP2A6*3, described as a hybrid allele
generated by multiple gene conversions with the inactive
CYP2A7 gene, has been proposed to be inactive [20] but
this has not yet been demonstrated.
Pianezza and co-workers [21] hypothesised that the
CYP2A6 genotype would be of importance for an individua’s
smoking behaviour. They showed that a lower number of
individuals carrying CYP2A6*2 and CYP2A6*3 alleles, de-
tected by the method described by Fernandez-Salguero et al,
[20], were found in a tobacco-dependent group as compared
to a never tobacco-dependent group and that subjects carry-
ing these alleles smoked fewer cigarettes. A recent study sup-
ports an important role for the CYP2A6 genotype in nicotine
metabolism in vivo, whereby individuals homozygous for a
CYP2A6 gene deletion displayed only 15% of the levels of
cotinine in urine as compared to subjects carrying at least
one active gene when they smoked the same number of ciga-
rettes [8]. Furthermore, Japanese subjects with a CYP2A6
gene deletion were shown to be at reduced risk for lung cancer
in a preliminary study [22].
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We have previously reported that the genotyping method
used for CYP2A6*2 in the studies by Pianezza and co-workers
[21] gave erroneous CYP2A6 phenotype predictions and de-
veloped an improved method for the detection of the
CYP2A6*2 allele [2]. In this report we have extended this
method for the accurate detection of the CYP2A6*3 allele
and show that it is not present among the Caucasian and
Chinese populations investigated. In addition, we have char-
acterised new CYP2A6 alleles whose presence might have im-
portant implications for the analysis of e.g. smoking behav-
iour and risk of lung cancer in relation to the CYP2A6
genotype.
2. Materials and methods
2.1. Subjects
Genomic DNA was obtained from Spanish subject H83 who was
previously scored as homozygous for the CYP2A6*3 allele [23]. Ge-
nomic DNA was also obtained from 100 Spaniards and 96 Chinese
individuals involved in earlier CYP2D6 genotype-phenotype correla-
tion studies [24,25]. The study was approved by the ethical committees
at Karolinska Institutet, the University of Oulu and the University
Hospital Infanta Cristina in Badajoz.
2.2. CYP2A6 genotyping
Genotyping for the CYP2A6*2 allele was performed as previously
described [2] with the addition of 0.25 WM of primers 2A6*3wt and
2A6*3mut, respectively (see Table 1) in PCR II for simultaneous
detection of the CYP2A6*3 allele. The corresponding region from
exon 1 to exon 4 of the CYP2A7 gene was used as a positive control
for the CYP2A6*3 allele.
A two-step PCR method was used to detect the CYP2A6*5 and
CYP2A6*1B alleles. In the ¢rst PCR reaction (PCR I), a region from
exon 8 to the 3P £anking region of the CYP2A6 gene was speci¢cally
ampli¢ed. This PCR product was subsequently used as a template in
the second allele-speci¢c PCR reaction (PCR II). PCR I was done
using primers 2A6ex8F and 2A6R1 (see Table 1). The reaction mix-
ture contained approximately 50 ng genomic DNA, 0.25 WM of each
primer, 0.2 mM of each dNTP, 1.0 mM MgCl2, 0.6 U of Taq poly-
merase (Life Technologies, Rockville, MD, USA) and was carried out
in 1UPCR Bu¡er (Life Technologies) in a total volume of 25 Wl using
a Perkin Elmer GeneAmp PCR system 2400/9700. Initial denaturation
was performed at 95‡C for 1 min, followed by 35 cycles each consist-
ing of denaturation at 95‡C for 15 s, annealing at 56‡C for 20 s, and
extension at 72‡C for 1.5 min, followed by a ¢nal extension at 72‡C
for 7 min.
The mixture for the CYP2A6*5 allele-speci¢c reaction (PCR II)
contained 0.8 Wl PCR I product, 0.25 WM of primer 2A6*5wt or
primer 2A6*5mut, 0.25 WM of primer 2A6R2 (see Table 1), 0.1 mM
of each dNTP, 1.0 mM MgCl2, 0.3 U of Taq polymerase, and was
done in 1U PCR bu¡er (Life Technologies) in a total volume of 25 Wl.
The ampli¢cation was performed by initial denaturation at 95‡C for
1 min, followed by 15 cycles each involving denaturation at 95‡C for
15 s, annealing at 54‡C for 20 s, and extension at 72‡C for 45 s. Ten Wl
of the PCR products were analysed on a 2% agarose gel (Life Tech-
nologies) stained with ethidium bromide. A similar method was used
for detection of the CYP2A6*1B allele, except that the primers
2A6*1Bwt and 2A6*1Bmut were used in PCR II.
2.3. Southern blot analysis
Southern Blot analysis with the restriction enzyme EcoRI was car-
ried out as previously reported [18].
2.4. Long PCR and DNA sequencing
Segments of the 5P £anking regions of the CYP2A6 and CYP2A7
genes were sequenced using cosmids 19296 and 19019 as templates
[26] (kindly supplied by Dr Linda K. Ashworth, LLNL Human Ge-
nome Center, Livermore, CA, USA). The CYP2A6 and CYP2A7
genes, as well as the CYP2A7/CYP2A6 hybrid, were ampli¢ed from
individual H83 using a GeneAmp XL PCR Kit (Perkin-Elmer, Nor-
walk, CT, USA) and di¡erent combinations of primers 2A6F1,
2A7F1, 2A6R1 and 2A7R1 (see Table 1). All exons, exon-intron
junctions and 5P and 3P £anking regions were sequenced with the
ABI Prism BigDye terminator cycle sequencing kit and analysed on
an ABI Prism 377 DNA sequencer.
2.5. Site-directed mutagenesis and subcloning of CYP2A6 cDNA into
the pYe60 yeast expression vector
A wt CYP2A6 cDNA [27] was used as a template in a PCR am-
pli¢cation with the eLONGase system (Life Technologies) using dif-
ferent combinations of the primers V60-2A6F, V60-2A6F-v5, V60-
2A6Rwt and V60-2A6Rmut (see Table 1) to produce constructs
with the two potential translation initiation sites with or without
the 1436GCT mutation in exon 9. The forward primers also intro-
duced an AAA in front of the translation initiation site which has
previously been shown to increase expression of CYP2D6 [28]. The
PCR fragments were subsequently cloned into the BamHI and KpnI
sites of the pYe60 (V60) yeast expression vector [29] and sequenced to
exclude any potential PCR artefacts.
2.6. Expression in yeast cells
Saccharomyces cerevisiae strain W(R) [30], which has been genet-
ically modi¢ed to overexpress the yeast cytochrome P450 reductase
gene (Yred), was transfected with the V60-2A6 plasmids described
above. Expression of CYP2A6 was carried out as previously described
[31,32] except that yeast cell microsomes were prepared by ultracen-
trifugation (100 000Ug for 60 min). Microsomal protein concentra-
tions and total cytochrome P450 content were determined with pre-
viously described methods [33,34].
2.7. Assay of CYP2A6 apoprotein levels and coumarin 7-hydroxylase
activity
To quantify apoprotein levels, 5 Wg of microsomal protein was
subjected to sodium dodecyl sulphate gel electrophoresis using a
10% polyacrylamide gel. The proteins were transferred to a nitrocel-
lulose ¢lter (Bio-Rad, Hemel Hempstead, UK), incubated with the
monoclonal CYP2A6 antibody MAB-2A6 (Gentest, Woburn, MA,
USA) and then with a secondary horseradish peroxidase-linked goat
anti-mouse antibody (Dako AS, Glostrup, Denmark). The enhanced
chemiluminescence method (Pierce, Rockford, IL, USA) was used to
visualise the CYP2A6 proteins.
Coumarin 7-hydroxylase activity was determined in reaction mix-
Fig. 1. Southern blot analysis of the CYP2A locus in genomic
DNA from individual H83 using the restriction endonuclease
EcoRI. C1 and C2 represent genomic DNA from control individuals
carrying two copies of the CYP2A6 gene.
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tures consisting of 100 mM Tris-HCl pH 7.4, 250 Wg of yeast micro-
somes and 100 WM of coumarin in a total volume of 500 Wl. The
reactions were initiated by addition of 0.5 Wmol of NADPH and
terminated with 500 Wl 6% trichloroacetic acid. The samples were
subsequently centrifuged at 15 000Ug for 10 min and the amount of
7-OH-coumarin formed was measured using a £uorometric method
[35].
3. Results
3.1. CYP2A6*3 genotyping
In order to accurately evaluate the presence of the
CYP2A6*3 allele and to avoid possible erroneous PCR am-
pli¢cation, we developed a modi¢ed method for its detection
using the primers in exon 1 and exon 4 that were previously
designed for CYP2A6-speci¢c ampli¢cation [2] with allele-spe-
ci¢c PCR primers that simultaneously detect the CYP2A6*2
and CYP2A6*3 alleles. Using this method, we could not ¢nd
any CYP2A6*3 allele in the two populations studied, namely
100 Spaniards and 96 Chinese individuals (Table 2). This is in
contrast to the 2^28% previously reported, indicating that the
great majority of the individuals who were found to be pos-
itive for the CYP2A6*3 allele with the method described by
Fernandez-Salguero and co-workers [20] are in fact false pos-
itives (see below).
3.2. Southern blot and sequencing of genomic DNA from
individual H83
To clarify the true origin of the alleles which were classi¢ed
Table 1
Primers used in the present study
Primer Sequence
V60-2A6F 5P-gatcagatctaaaatgctggcctcagggatgcttctggtggcc-3P
V60-2A6F-v5 5P-gatcagatctaaaatgcttctggtggccttgctg-3P
V60-2A6Rwt 5P-gatcggtacctcagcggggcaggaagctcatg-3P
V60-2A6Rmut 5P-gatcggtacctcagcggggcaggaagctcatggtgtagtttcgtgggatcgtggcaaagaccacgtg-3P
2A6ex1a 5P-gctgaacacagagcagatgtaca-3P
2A6ex4Ra 5P-ggaggttgacgtgaactggaaga-3P
2A6*2wta 5P-ctcatcgacgccct-3P
2A6*2muta 5P-ctcatcgacgccca-3P
2A6*3wt 5P-gctccggcgcttct-3P
2A6*3mut 5P-gctcctgcgctttg-3P
E3Rb 5P-tcgtcctgggtgttttccttc-3P
2A6F1 5P-tggctgtgtcccaagctaggca-3P
2A7F1 5P-tggctgtgtcccaagctaggtg-3P
2A6R1c 5P-gcacttatgttttgtgagacatcagagacaa-3P
2A7R1 5P-gcacttatgttttgtgagacatcagatagag-3P
2A6R2c 5P-aaaatgggcatgaacgccc-3P
2A6ex8F 5P-ccagcacttcctgaatgag-3P
2A6*5wt 5P-ccccaaacacgtggg-3P
2A6*5mut 5P-ccccaaacacgtggt-3P
2A6*1Bwt 5P-actgggggcaggatggc-3P
2A6*1Bmut 5P-aatggggggaagatgcg-3P
Restriction enzyme sites used for cloning are underlined.
aFrom Oscarson et al. [2].
bFrom Fernandez-Salguero et al. [20].
cFrom Oscarson et al. [18].
Table 2
CYP2A6 genotypes and allele frequencies in a Spanish and a Chinese population determined by allele-speci¢c PCR methods
Population
Spaniards (n = 100) Chinese (n = 96)
Genotypes (%)
CYP2A6*1A/CYP2A6*1A 48.0 19.8
CYP2A6*1A/CYP2A6*1B 33.0 36.5
CYP2A6*1B/CYP2A6*1B 12.0 14.6
CYP2A6*1A/CYP2A6*2 4.0 0
CYP2A6*1B/CYP2A6*2 2.0 0
CYP2A6*1A/CYP2A6*4 0 10.4
CYP2A6*1B/CYP2A6*4 1.0 13.5
CYP2A6*4/CYP2A6*4 0 3.1
CYP2A6*1B/CYP2A6*5 0 2.1
Alleles (%) Functional consequence
CYP2A6*1A wt 66.5 43.2
CYP2A6*1B gene conversion in the 3P £anking region 30.0 40.6
CYP2A6*2 L160H 3.0 0
CYP2A6*3 multiple CYP2A6/CYP2A7 gene conversions 0 0
CYP2A6*4 CYP2A6 gene deletion 0.5 15.1
CYP2A6*5 G479L 0 1.0
Data compiled from this and previous studies [2,18].
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as CYP2A6*3, we took advantage of an individual (H83) who
was consistently scored as homozygous for the CYP2A6*3
allele when assayed with the original genotyping method
[20] but was homozygous for the CYP2A6*1 allele with our
genotyping method. Interestingly, phenotyping with the
CYP2A6 probe drug coumarin demonstrated that this indi-
vidual completely lacked CYP2A6 activity in vivo (data not
shown).
Restriction fragment length polymorphism analysis of ge-
nomic DNA from individual H83 showed that one of the
CYP2A genes was deleted (Fig. 1). Using di¡erent combina-
tions of CYP2A6- and CYP2A7-speci¢c primers in the 5P and
3P £anking regions, it was possible to amplify a CYP2A6 gene,
a CYP2A7 gene as well as a CYP2A7/CYP2A6 hybrid from
this individual. The PCR products were subjected to DNA
sequencing of all the exons and exon-intron junctions. The
coding region of the CYP2A6 allele was identical to the
CYP2A6 cDNA sequence previously reported [17] except for
a 1436GCT mutation in exon 9, yielding a G479L substitu-
tion. In addition, a gene conversion event with the CYP2A7
gene was found in the 3P £anking region (Fig. 2). This allele
was designated CYP2A6*5.
Sequencing of the CYP2A7/CYP2A6 hybrid revealed that it
was consistent with a deletion of the CYP2A6 gene, which
most likely occurred through an unequal crossover event in
a similar way as the CYP2A6 gene deletion previously re-
ported in Chinese individuals (CYP2A6*4A) [18]. Because
exon 1 to exon 8 consists of the CYP2A7 sequence and the
3P £anking region has the CYP2A6 sequence, we concluded
that the crossover junction region is located in either intron 8
or exon 9, in contrast to the CYP2A6*4A allele where it is
located in the 3P £anking region. This new type of deletion
was designated CYP2A6*4D and can also be detected using
our PCR-based genotyping method for CYP2A6 deletions [18]
(data not shown).
3.3. Expression of CYP2A6*5 in S. cerevisiae
In order to evaluate the e¡ect of the G479L substitution on
the CYP2A6 enzyme, the 1436GCT mutation was introduced
into a wt CYP2A6 cDNA. Furthermore, two di¡erent N-ter-
minal variants were generated to correspond to the two po-
tential translation initiation sites reported [17,27]. Heterolo-
gous expression of the di¡erent constructs in S. cerevisiae
revealed that the ¢rst translation initiation site resulted in
substantially higher expression levels in our system (Table 3
and Fig. 3). Introduction of the G479L substitution gave an
enzyme variant (CYP2A6.5) which was only expressed at very
low levels with a concomitant lack of coumarin 7-hydroxyla-
tion activity (Table 3 and Fig. 3), indicating that this substi-
tution yields a much less stable enzyme that is rapidly de-
graded.
3.4. CYP2A6*1B and CYP2A6*5 genotyping
A PCR-based genotyping method was developed to detect
the CYP2A6*5 allele and was used to genotype two di¡erent
populations (Fig. 4). It was determined that this allele was
very rare in the Chinese and Spanish populations examined,
with an allele frequency of 0^1% (Table 2).
Interestingly, the CYP2A6*5 allele also contained a gene
Fig. 3. Western blot analysis of the CYP2A6 enzyme variants ex-
pressed in S. cerevisiae. Experimental conditions are described in
Section 2 and the samples are labelled as described in Table 3, with
V60 representing yeast transfected with an empty vector.
Fig. 4. Allele-speci¢c PCR to detect the CYP2A6*5 and CY-
P2A6*1B alleles (‘PCR II’). MW, 1 kb plus DNA ladder (Life
Technologies, Rockville, MD, USA). Genotypes of the subjects are:
Ch123 (CYP2A6*1A/*1A), Ch102 (CYP2A6*1B/*5), Ch103 (CY-
P2A6*1A/*1B), H83 (CYP2A6*4D/*5).
Table 3
Characterisation of yeast microsomes from the S. cerevisiae P450 reductase overexpressing strain W(R) transfected with CYP2A6*1 and
CYP2A6*5 alleles
Enzyme variant P450 holoprotein level (pmol/mg microsomal protein) Coumarin 7-OH activity (pmol/min/mg microsomal protein)
CYP2A6.1 44 þ 21 310 þ 140
v5-CYP2A6.1 ND ND
CYP2A6.5 ND ND
v5-CYP2A6.5 ND ND
In enzyme variants labelled with v5, the second potential translation initiation site was used. The data represent mean þ S.D. of experiments
from 2^6 batches of transfected cells. ND, not detectable.
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conversion with the CYP2A7 gene in the 3P £anking region of
the CYP2A6 gene. This is the region where the reverse primer
R4 is located in the original genotyping method [20] and re-
sults in a failure to amplify the CYP2A6 gene. Genotyping for
this gene conversion revealed an allele frequency of 30.0 and
40.6% in the Spanish and Chinese populations, respectively
(Fig. 4 and Table 2). Its presence most likely explains the
high frequency of the CYP2A6*3 allele previously reported
(see below). This allele, without the 1436GCT mutation,
was denoted CYP2A6*1B.
4. Discussion
In this report we have identi¢ed and characterised two nov-
el inactive CYP2A6 alleles, the CYP2A6*5 allele which has a
1436GCT mutation in exon 9 yielding a G479L substitution
and CYP2A6*4D, a novel CYP2A6 gene deletion variant. In
addition, we found a common CYP2A7 gene conversion in
the 3P £anking region of the CYP2A6 gene. An overview of
the known CYP2A6 alleles that have been generated through
di¡erent unequal crossover events is shown in Fig. 5.
The 1436GCT mutation is also found in one of the
CYP2A7 sequences reported (accession number U22029
[20]), therefore it is likely that this mutation has been trans-
ferred from the related CYP2A7 gene through various cross-
over events. This is in analogy with e.g. the CYP21 and
CYP2D6 genes, where it appears that many of the inactivating
mutations are continuously transferred from the correspond-
ing pseudogenes CYP21P and CYP2D7P [36,37]. The G479
amino acid residue is located in substrate recognition site 6
[38] and is highly conserved in the CYP2A, CYP2B and
CYP2F subfamilies. All of the 28 P450s in these subfamilies
that have been reported to the SwissProt database, except
CYP2A8 from golden hamster, have a glycine residue at the
corresponding position. This indicates an important structural
function for this residue, which is often the case for glycine
residues, and consistent with our ¢ndings that showed the
G479L substitution to yield a very unstable enzyme. We can-
not, however, exclude that this mutation caused a decrease in
mRNA stability or translation e⁄ciency.
We have demonstrated that the commonly used CYP2A6
genotyping method [20] gives erroneous results with respect to
the CYP2A6*3 allele, the predominant allele in many studies
which is considered to be inactive. This method is based on
initial ampli¢cation of the whole CYP2A6 gene with the prim-
ers F4 and R4, followed by ampli¢cation of the diagnostic
exon 3 and subsequent digestion with the restriction enzymes
XcmI and DdeI. In the second PCR reaction, 31 cycles of
ampli¢cation are used, and this high number of cycles is
enough for the ampli¢cation of carry-over genomic DNA in
cases where the ¢rst PCR reaction failed for some reason. In
individual H83, this method does not amplify the CYP2A6*5
allele because of the gene conversion in the 3P £anking region.
Instead, the CYP2A7/CYP2A6 hybrid is ampli¢ed from the
CYP2A6*4D allele which has the CYP2A6 sequence in the 3P
£anking region. Further analysis of exon 3 reveals only the
CYP2A7 sequence and the individual is therefore erroneously
scored as homozygous for the CYP2A6*3 allele.
Interestingly, genomic DNA from the 12^15% of the pop-
ulation that are homozygous for the CYP2A6*1B allele would
not be ampli¢ed in the ¢rst PCR reaction using the original
method. However, both the CYP2A6 and CYP2A7 genes
would be ampli¢ed from the carry-over genomic DNA and
these individuals would be erroneously scored as heterozygous
for the CYP2A6*3 allele (data not shown). This most likely
explains the high CYP2A6*3 allele frequency reported in
many studies [20,23,39].
We conclude that it is very important that all genotyping
methods are validated in large populations of phenotyped
individuals before they are used in molecular epidemiological
studies. This is especially important when complex genetic loci
are analysed and the risk of coampli¢cation of related genes
exist. The method used by Pianezza and co-workers [21] de-
tects a high frequency of the CYP2A6*3 allele, whereas our
more speci¢c genotyping method revealed the complete ab-
sence of this allele. The negligible frequency of the
CYP2A6*3 allele has also been con¢rmed in two recent stud-
ies [8,40]. There is a growing need for accurate genotype-phe-
notype studies with respect to a true evaluation of the hypoth-
esis raised by Pianezza and co-workers, and the genotyping
methods and new alleles presented here will aid in further
investigations in this ¢eld.
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the pYeD60 vector. The study was supported by grants from the
Swedish Society for Medical Research, Swedish Match and the Swed-
ish Medical Research Council.
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